<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ALPROSTADIL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ALPROSTADIL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Erectile dysfunction (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By urethral application</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 250 micrograms, adjusted according to response; usual dose 0.125&#8211;1 mg; maximum 2 doses per day; maximum 7 doses per week.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Aid to diagnosis of erectile dysfunction</span>,
            </h4>
            <p class="specificity"><span class="route">By urethral application</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Erectile dysfunction</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 300 micrograms, to the tip of the penis, 5&#8211;30 minutes before sexual activity; max 1 dose in 24 hours not more than 2&#8211;3 times per week.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>






      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Not for use in patients with penile implants or when sexual activity medically inadvisable (e.g. orthostatic hypotension, myocardial infarction, and syncope)</li>
            <li>not for use with other agents for erectile dysfunction</li>
            <li>predisposition to prolonged erection (as in thrombocythemia, polycythemia, sickle cell anaemia, multiple myeloma or leukaemia)</li>
            <li>urethral application contra-indicated in balanitis</li>
            <li>urethral application contra-indicated in severe curvature</li>
            <li>urethral application contra-indicated in severe hypospadia</li>
            <li>urethral application contra-indicated in urethral stricture</li>
            <li>urethral application contra-indicated in urethritis</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Dizziness, haematoma, haemosiderin deposits, headache, hypertension, hypotension, influenza-like syndrome, injection site reactions, other localised pain (buttocks, leg, testicular, abdominal), penile fibrosis, penile oedema, penile pain, penile rash, urethral bleeding, urethral burning,
              </p>
              <p>
                <strong>uncommon:</strong> Abnormal ejaculation, asthenia, balantitis, dry mouth, haematuria, irritation, leg cramps, local reactions, micturation difficulties, mydriasis, nausea, pelvic pain, penile numbness or sensitivity, penile warmth, phimosis, priapism, pruritus, rapid pulse, scrotal erythema, scrotal oedema, scrotal pain, supraventricular extrasystole, sweating, syncope, testicular oedema, testicular thickening, urethral stenosis, vasodilatation,
              </p>
              <p>
                <strong>rare:</strong> Anaphylaxis, erythema, hypersensitivity reactions, rash, urinary-tract infection, urticaria, vertigo,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intracavernosal</ph> use</h3>
              <p>The first dose of the intracavernosal injection must be given by medically trained personnel; self-administration may only be undertaken after proper training.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">urethral</ph> use</h3>
              <p>During initiation of treatment the urethral application should be used under medical supervision; self-administration may only be undertaken after proper training.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients should be instructed to report any erection lasting 4 hours or longer.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Counsel patients that condoms should be used to avoid local reactions and exposure of alprostadil to women of childbearing age, pregnant, or lactating women.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Anatomical deformations of penis (painful erection more likely)&#8212;follow up regularly to detect signs of penile fibrosis (consider discontinuation if angulation, cavernosal fibrosis or Peyronie&#8217;s disease develop)
          </li>
          <li>
            priapism (patients should be instructed to report any erection lasting 4 hours or longer)
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">urethral</ph> use</h3>
              <p>If partner is pregnant, barrier contraception should be used. No evidence of harm to latex condoms and diaphragms.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Condoms should be used to avoid exposure to women of child-bearing age, pregnant or lactating women. No evidence of harm to latex condoms.</p>
            </section>
      </section>












      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ALPROSTADIL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76639"><a href="../medicinalForm/PHP76639.html" data-target="#PHP76639" data-action="load">Powder and solvent for solution for injection</a></div>
            <div id="PHP76624"><a href="../medicinalForm/PHP76624.html" data-target="#PHP76624" data-action="load">Solution for infusion</a></div>
            <div id="PHP101333"><a href="../medicinalForm/PHP101333.html" data-target="#PHP101333" data-action="load">Cream</a></div>
            <div id="PHP76617"><a href="../medicinalForm/PHP76617.html" data-target="#PHP76617" data-action="load">Stick</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
